Arax Advisory Partners Has $1.60 Million Stake in Cencora, Inc. $COR

Arax Advisory Partners trimmed its position in shares of Cencora, Inc. (NYSE:COR) by 56.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,733 shares of the company’s stock after selling 6,054 shares during the quarter. Arax Advisory Partners’ holdings in Cencora were worth $1,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Oakworth Capital Inc. acquired a new stake in shares of Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the 4th quarter valued at about $27,000. Archer Investment Corp lifted its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at about $30,000. Finally, Caitlin John LLC acquired a new stake in shares of Cencora during the 3rd quarter valued at about $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on COR shares. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Robert W. Baird cut their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Wells Fargo & Company cut their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Barclays cut their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a research note on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $374.00.

Cencora Stock Performance

Shares of NYSE COR opened at $281.58 on Tuesday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The business’s 50 day moving average is $288.36 and its two-hundred day moving average is $326.67. The company has a market cap of $54.78 billion, a P/E ratio of 21.59, a P/E/G ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has authorized a stock buyback program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.